Plegridy Satisfaction Study in Participants

PHASE4CompletedINTERVENTIONAL
Enrollment

193

Participants

Timeline

Start Date

February 3, 2016

Primary Completion Date

October 2, 2017

Study Completion Date

December 21, 2017

Conditions
Relapsing-Remitting Multiple Sclerosis (RRMS)
Interventions
DRUG

peginterferon beta-1a

125 mcg administered subcutaneously (SC) every 2 weeks.

Trial Locations (30)

10043

Research Site, Orbassano

10126

Research Site, Torino

12084

Research Site, Mondovì

16132

Research Site, Genova

17027

Research Site, Pietra Ligure

20132

Research Site, Milan

20133

Research Site, Milan

21013

Research Site, Gallarate

22100

Research Site, Como

27100

Research Site, Pavia

41126

Research Site, Modena

43036

Research Site, Fidenza

52100

Research Site, Arezzo

66100

Research Site, Chieti

67100

Research Site, L’Aquila

70124

Research Site, Bari

80131

research Site, Napoli

80137

Research Site, Napoli

86077

Research Site, Pozzilli

89100

Research Site, Reggio Calabria

90015

Research Site, Cefalù

90129

Research Site, Palermo

90146

Research Site, Palermo

98125

Research Site, Messina

09126

Research Site, Cagliari

06034

Research Site, Foligno

07014

Research Site, Ozieri

00152

Research Site, Roma

00168

Research Site, Roma

00189

Research Site, Roma

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY